Citations (181)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (17)
Dayanand Swami, Priyanka Mudaliar, Yash Shrinivas Bichu, Vishal Kumar Sahu, Shine Devarajan, Soumya Basu & Jyotirmoi Aich. (2023) Synergistic combination of ritonavir and cisplatin as an efficacious therapy in human cervical cancer cells: a computational drug discovery and in vitro insight. Journal of Biomolecular Structure and Dynamics 41:12, pages 5802-5816.
Read now
Read now
Deyi Ma, Mengrao Guo & Xin Zhai. (2023) An updated patent review of anaplastic lymphoma kinase inhibitors (2018–2022). Expert Opinion on Therapeutic Patents 33:4, pages 323-337.
Read now
Read now
Liaba Niaz, Furqan Ahmad Saddique, Sana Aslam, Matloob Ahmad & Noor ul Amin Mohsin. (2020) Recent synthetic methodologies for pyridopyrazines: An update. Synthetic Communications 50:18, pages 2755-2786.
Read now
Read now
Hui Yu, Si Sun, Xingjiang Hu, Jinjing Xia, Jialei Wang & Haiquan Chen. (2019) Chinese perspectives on clinical efficacy and safety of alectinib in patients with ALK-positive advanced non-small cell lung cancer. OncoTargets and Therapy 12, pages 6481-6495.
Read now
Read now
Niki Karachaliou, Manuel Fernandez Bruno, Jillian Wilhelmina Paulina Bracht & Rafael Rosell. (2019) Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives. OncoTargets and Therapy 12, pages 4567-4575.
Read now
Read now
Nobuo Sekiguchi, Shunsuke Nagao, Kenji Takanashi, Motohiro Kato, Akihisa Kaneko, Keiichi Morita, Hidetoshi Shindoh & Masaki Ishigai. (2017) Preclinical evaluation of the potential for cytochrome P450 inhibition and induction of the selective ALK inhibitor, alectinib. Xenobiotica 47:12, pages 1042-1051.
Read now
Read now
Manli Jiang, N. Nora Bennani & Andrew L. Feldman. (2017) Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms. Expert Review of Hematology 10:3, pages 239-249.
Read now
Read now
Lisa M. Kopp & Emmanuel Katsanis. (2016) Targeted immunotherapy for pediatric solid tumors. OncoImmunology 5:3.
Read now
Read now
Zhihong Zhao, Vivek Verma & Mutian Zhang. (2015) Anaplastic lymphoma kinase: Role in cancer and therapy perspective. Cancer Biology & Therapy 16:12, pages 1691-1701.
Read now
Read now
Xueyan Chen, Lorinda A Soma & Jonathan R Fromm. (2014) Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin. OncoTargets and Therapy 7, pages 45-56.
Read now
Read now
Francesca Farina, Alessandra Stasia & Carlo Gambacorti-Passerini. (2014) Developments in anaplastic large-cell lymphoma: targeting the anaplastic lymphoma kinase. Blood and Lymphatic Cancer: Targets and Therapy 4, pages 69-79.
Read now
Read now
Eugen F Mesaros, Gregory R Ott & Bruce D Dorsey. (2014) Anaplastic lymphoma kinase inhibitors as anticancer therapeutics: a patent review. Expert Opinion on Therapeutic Patents 24:4, pages 417-442.
Read now
Read now
Garrett M Brodeur, Radhika Iyer, Jamie L Croucher, Tiangang Zhuang, Mayumi Higashi & Venkatadri Kolla. (2014) Therapeutic targets for neuroblastomas. Expert Opinion on Therapeutic Targets 18:3, pages 277-292.
Read now
Read now
Eric J. Lowe & Thomas G. Gross. (2013) Anaplastic Large Cell Lymphoma in Children and Adolescents. Pediatric Hematology and Oncology 30:6, pages 509-519.
Read now
Read now
Anna Kruczynski, Georges Delsol, Camille Laurent, Pierre Brousset & Laurence Lamant. (2012) Anaplastic lymphoma kinase as a therapeutic target. Expert Opinion on Therapeutic Targets 16:11, pages 1127-1138.
Read now
Read now
Rebecca A Howman & H Miles Prince. (2011) New drug therapies in peripheral T-cell lymphoma. Expert Review of Anticancer Therapy 11:3, pages 457-472.
Read now
Read now
Karen L Milkiewicz & Gregory R Ott. (2010) Inhibitors of anaplastic lymphoma kinase: a patent review. Expert Opinion on Therapeutic Patents 20:12, pages 1653-1681.
Read now
Read now
Articles from other publishers (164)
Qi-An Wang, Huan-Wu Chen, Ren-Chin Wu & Chiao-En Wu. (2023) Update of Diagnosis and Targeted Therapy for ALK+ Inflammation Myofibroblastic Tumor. Current Treatment Options in Oncology.
Crossref
Crossref
Muhammad Rashid, Muhammad Khalid, Abida Ashraf, Tahira Saleem, Iqra Shafiq, Muhammad Azeem Shakil, Briha Zainab, Attalla F. El-kott, Muhammad Yaqub & Zahid Shafiq. (2023)
Multicomponent synthesis of pyrido[2,3-
b
]pyrazine derivatives: electrochemical DNA sensing, nonlinear optical properties and biological activity
. RSC Advances 13:46, pages 32160-32174.
Crossref
Crossref
Megha Yadav, Blessi N. Uikey, Shantnu Singh Rathore, Priyanka Gupta, Diksha Kashyap, Chanchal Kumar, Dhananjay Shukla, Vijayamahantesh, Arvind Singh Chandel, Bharti Ahirwar, Ashish Kumar Singh, Shashi Shekhar Suman, Amit Priyadarshi & Ajay Amit. (2023) Role of cytokine in malignant T-cell metabolism and subsequent alternation in T-cell tumor microenvironment. Frontiers in Oncology 13.
Crossref
Crossref
Xin Liu, Chengcheng Gong, Jieyun Zhang, Wanjing Feng, Yanjing Guo, Youzhou Sang, Chunmeng Wang, Yong Chen, Jian Wang, Lin Yu, Xiaowei Zhang & Zhiguo Luo. (2023) Clinicopathological Analysis and Treatment of Adult Patients with Inflammatory Myofibroblastic Tumor: A 15-Year Single-Center Study. Cancer Research and Treatment 55:3, pages 1001-1010.
Crossref
Crossref
Md Shahid Ayaz, Ritu Bhupal, Priyanka Sharma, Adarsh Sahu, Parwati Singh, Ghanshyam Das Gupta & Vivek Asati. (2023) Recent Updates on Structural Aspects of ALK Inhibitors as an Anticancer Agent. Anti-Cancer Agents in Medicinal Chemistry 23:8, pages 900-921.
Crossref
Crossref
Vladimira Tichà, Gianluigi Patelli, Gianpaolo Basso, Aurelio Prino, Elena Repetti, Maria Grugni & Bruno Damascelli. (2023) Case Report: Potential role of selective venous sampling for liquid biopsy in complex clinical settings: Three case presentations. Frontiers in Genetics 14.
Crossref
Crossref
Lara J. Bou Malhab, Habiba Alsafar, Saleh Ibrahim & Mohamed Rahmani. (2023) PROTACs: Walking through hematological malignancies. Frontiers in Pharmacology 14.
Crossref
Crossref
Pier Paolo Piccaluga, Chiara Cascianelli & Giorgio Inghirami. (2023) Tyrosine kinases in nodal peripheral T-cell lymphomas. Frontiers in Oncology 13.
Crossref
Crossref
Shrinidhi Nathany, Mansi Sharma & Ullas Batra. (2023) ALK-driven NSCLC: A narrative review - Part I. Cancer Research, Statistics, and Treatment 6:2, pages 272-278.
Crossref
Crossref
V. Pratap Reddy Gajulapalli, Juyong Lee & Insuk Sohn. (2023) Ligand-based pharmacophore modelling in search of novel anaplastic lymphoma kinase inhibitors. Results in Chemistry 5, pages 100752.
Crossref
Crossref
Fabian De Smedt, Frédérique Dessy, Luciano Carestia, Pamela Baldin, Frank Nana, Philippe Clapuyt, Véronique Boon, Frédéric Amant & Mina Gziri. (2022) A pregnant patient with ALK‑positive non‑small cell lung cancer treated with alectinib: A case report and review of the literature. Oncology Letters 25:2.
Crossref
Crossref
Hye-Young Min & Ho-Young Lee. (2022) Molecular targeted therapy for anticancer treatment. Experimental & Molecular Medicine 54:10, pages 1670-1694.
Crossref
Crossref
Vivek Sanker, Azeem Mohamed, Maanasi Pranala, Chaithra Jadhav & Varghese Tharakan. (2022) Primary Anaplastic Lymphoma Kinase (ALK)-Negative Anaplastic Large Cell Lymphoma (ALCL) Presenting as Perforation Peritonitis: A Case Report and Management Principles. Cureus.
Crossref
Crossref
Gang-Long Jiang, Lian-Hua Song, Yong-Fu Qiu & Yu Liu. (2022) 3D-QSAR and Docking Studies on Pyrimidine Derivatives of Second-Generation ALK Inhibitors. Pharmaceutical Fronts 04:03, pages e136-e150.
Crossref
Crossref
Sonia Thapa, Rafiq A. Rather, Shashank K. Singh & Madhulika Bhagat. 2022. Molecular Mechanisms in Cancer. Molecular Mechanisms in Cancer.
Thanh-Diem Nguyen, Ly Le, Tu-Binh Vo, Kim-Lan Vo, Hoang-Minh Le & Huyen-Trang Vu. (2022) Evaluation of Colorectal Cancer Inhibition Ability of Rosmarinus officinalis L. via Molecular Docking and Pharmacophore Analysis. International Journal of Pharmacology 18:2, pages 262-278.
Crossref
Crossref
Chaoling Chen, Dengpiao Xie, David A. Gewirtz & Ningjun Li. 2022. Strategies to Mitigate the Toxicity of Cancer Therapeutics. Strategies to Mitigate the Toxicity of Cancer Therapeutics
77
129
.
Andrea Ferrari & Rita Alaggio. 2022. Rare Tumors in Children and Adolescents. Rare Tumors in Children and Adolescents
535
582
.
Dina Erzina, Alice Capecchi, Sacha Javor & Jean‐Louis Reymond. (2021) An Immunomodulatory Peptide Dendrimer Inspired from Glatiramer Acetate. Angewandte Chemie International Edition 60:50, pages 26403-26408.
Crossref
Crossref
Dina Erzina, Alice Capecchi, Sacha Javor & Jean‐Louis Reymond. (2021) An Immunomodulatory Peptide Dendrimer Inspired from Glatiramer Acetate. Angewandte Chemie 133:50, pages 26607-26612.
Crossref
Crossref
Yi-Lin Chen, Wan-Li Chen, Yi-Chia Cheng, Ming-Ching Lin, Shu-Ching Yang, Hung-Wen Tsai, Chien‐Chung Lin, Wu-Chou Su, Nan-Haw Chow & Chung-Liang Ho. (2021) Development of a novel ALK rearrangement screening test for non–small cell lung cancers. PLOS ONE 16:9, pages e0257152.
Crossref
Crossref
Muhamad Mustafa, Amer Ali Abd El-Hafeez, Dalia A Abdelhafeez, Dalia Abdelhamid, Yaser A Mostafa, Pradipta Ghosh, Alaa M Hayallah & Gamal El-Din A Abuo-Rahma. (2021) FAK inhibitors as promising anticancer targets: present and future directions. Future Medicinal Chemistry 13:18, pages 1559-1590.
Crossref
Crossref
Feng Wu, Han Yao, Wei Li, Niuniu Zhang, Yangyang Fan, Albert S.C. Chan, Xingshu Li & Baijiao An. (2021) Synthesis and evaluation of novel 2,4-diaminopyrimidines bearing a sulfoxide moiety as anaplastic lymphoma kinase (ALK) inhibition agents. Bioorganic & Medicinal Chemistry Letters 48, pages 128253.
Crossref
Crossref
Debasis Das, Jingbing Wang & Jian Hong. (2021) Next‐Generation Kinase Inhibitors Targeting Specific Biomarkers in Non‐Small Cell Lung Cancer (NSCLC): A Recent Overview. ChemMedChem 16:16, pages 2459-2479.
Crossref
Crossref
Priya Mahajan, Michela Casanova, Andrea Ferrari, Ashleigh Fordham, Toby Trahair & Rajkumar Venkatramani. (2021) Inflammatory myofibroblastic tumor: molecular landscape, targeted therapeutics, and remaining challenges. Current Problems in Cancer 45:4, pages 100768.
Crossref
Crossref
Jing Li, Yubing Wang, Lisha Li, Penelope M.‐Y. Or, Chi Wai Wong, Tian Liu, Wayne L.H. Ho & Andrew M. Chan. (2021) Tumour‐derived substrate‐adherent cells promote neuroblastoma survival through secreted trophic factors. Molecular Oncology 15:8, pages 2011-2025.
Crossref
Crossref
Veena Gullapalli, Wen Xu, Craig R. Lewis, Antoinette Anazodo & Giselle Kidson Gerber. (2021) A multi-centre case series of alectinib-related erythrocyte membrane changes and associated haemolysis. Journal of Hematopathology 14:2, pages 131-136.
Crossref
Crossref
Parteek Prasher & Mousmee Sharma. (2021) Medicinal Chemistry of Indane and Its Analogues: A Mini Review. ChemistrySelect 6:11, pages 2658-2677.
Crossref
Crossref
Yun-peng Li, Wen-wen Han, Le-jian He, Wen-tao Zheng & Wei-ping Zhang. (2021) Inflammatory Myofibroblastic Tumor After Treatment of Wilms Tumor in a 6-Year-Old Boy: A Case Report and Literature Review. Urology 149, pages e25-e28.
Crossref
Crossref
Jianzhong Chen, Wei Wang, Haibo Sun, Laixue Pang & Baohua Yin. (2020) Mutation-mediated influences on binding of anaplastic lymphoma kinase to crizotinib decoded by multiple replica Gaussian accelerated molecular dynamics. Journal of Computer-Aided Molecular Design 34:12, pages 1289-1305.
Crossref
Crossref
Jianyong Chen, Yunlong Zhou, Xuyuan Dong, Liu Liu, Longchuan Bai, Donna McEachern, Sally Przybranowski, Chao-Yie Yang, Jeanne Stuckey, Xiaoqin Li, Bo Wen, Ting Zhao, Siwei Sun, Duxin Sun, Lingling Jiao, Yu Jing, Ming Guo, Dajun Yang & Shaomeng Wang. (2020) Discovery of CJ-2360 as a Potent and Orally Active Inhibitor of Anaplastic Lymphoma Kinase Capable of Achieving Complete Tumor Regression. Journal of Medicinal Chemistry 63:22, pages 13994-14016.
Crossref
Crossref
Giacomo Giulio Baldi, Mehdi Brahmi, Salvatore Lo Vullo, Elena Cojocaru, Olivier Mir, Michela Casanova, Bruno Vincenzi, Tommaso Martino De Pas, Giovanni Grignani, Maria Abbondanza Pantaleo, Jean Yves Blay, Robin Lewis Jones, Axel Le Cesne, Anna Maria Frezza, Alessandro Gronchi, Paola Collini, Angelo Paolo Dei Tos, Carlo Morosi, Luigi Mariani, Paolo Giovanni Casali & Silvia Stacchiotti. (2020) The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors: A Multicenter, European Retrospective Case Series Analysis. The Oncologist 25:11, pages e1777-e1784.
Crossref
Crossref
Yun-peng Li, Wen-wen Han, Yang Yang, Le-jian He & Wei-ping Zhang. (2020) Inflammatory Myofibroblastic Tumor of the Urinary Bladder and Ureter in Children: Experience of a Tertiary Referral Center. Urology 145, pages 229-235.
Crossref
Crossref
Sina Abedi, Gregory Yung, Shari R. Atilano, Kunal Thaker, Steven Chang, Marilyn Chwa, Kevin Schneider, Nitin Udar, Daniela Bota & M. Cristina Kenney. (2020) Differential effects of cisplatin on cybrid cells with varying mitochondrial DNA haplogroups. PeerJ 8, pages e9908.
Crossref
Crossref
Jungjoong Hwang, Insuk Song, Kwangho Lee, Hyoung Rae Kim, Eun-Hye Hong, Jung Soon Hwang, Sung-Hoon Ahn & Jongkook Lee. (2020) KRCA-0008 suppresses ALK-positive anaplastic large-cell lymphoma growth. Investigational New Drugs 38:5, pages 1282-1291.
Crossref
Crossref
Sirajam Munira, Ryuzaburo Yuki, Youhei Saito & Yuji Nakayama. (2020) ALK Inhibitors-Induced M Phase Delay Contributes to the Suppression of Cell Proliferation. Cancers 12:4, pages 1054.
Crossref
Crossref
Michela Casanova, Bernadette Brennan, Rita Alaggio, Anna Kelsey, Daniel Orbach, Max M. van Noesel, Nadege Corradini, Veronique Minard-Colin, Ilaria Zanetti, Gianni Bisogno, Soledad Gallego, Johannes H.M. Merks, Gian Luca De Salvo & Andrea Ferrari. (2020) Inflammatory myofibroblastic tumor: The experience of the European pediatric Soft Tissue Sarcoma Study Group (EpSSG). European Journal of Cancer 127, pages 123-129.
Crossref
Crossref
D. Sam Daniel Prabu, Sivalingam Lakshmanan, K. Thirumurugan, N. Ramalakshmi & S. Arul Antony. (2020) Synthesis, Molecular Docking, DFT Study of Novel N-Benzyl-2-(3-cyano-4-isobutoxyphenyl)-
4-methylthiazole-5-carboxamide Derivatives and their Antibacterial Activity. Asian Journal of Chemistry 32:3, pages 619-626.
Crossref
Crossref
Mikiko Nagashima, Travis S. D'Cruz, Antoinette E. Danku, Doneen Hesse, Christopher Sifuentes, Pamela A. Raymond & Peter F. Hitchcock. (2020) Midkine-a Is Required for Cell Cycle Progression of Müller Glia during Neuronal Regeneration in the Vertebrate Retina. The Journal of Neuroscience 40:6, pages 1232-1247.
Crossref
Crossref
Atefeh Kheyrollahiyan, Akbar Sharifi & Mohammad Mirza-Aghazadeh-Attari. (2019) Systemic anaplastic large cell lymphoma presenting as a huge mediastinal mass in a case of hyper IgE syndrome: a case report. Egyptian Journal of Radiology and Nuclear Medicine 50:1.
Crossref
Crossref
Claire Y. Oh, Martin G. Klatt, Christopher Bourne, Tao Dao, Megan M. Dacek, Elliott J. Brea, Sung Soo Mun, Aaron Y. Chang, Tatyana Korontsvit & David A. Scheinberg. (2019) ALK and RET Inhibitors Promote HLA Class I Antigen Presentation and Unmask New Antigens within the Tumor Immunopeptidome. Cancer Immunology Research 7:12, pages 1984-1997.
Crossref
Crossref
Hong Chen, Ridong Li, Xianling Ning, Xuyang Zhao, Yan Jin & Yuxin Yin. (2019) Synthesis and anti-tumor efficacy of novel 2, 4-diarylaminopyrimidine derivatives bearing N-(3-pyridinylmethyl) urea moiety as anaplastic lymphoma kinase inhibitors. European Journal of Medicinal Chemistry 178, pages 141-153.
Crossref
Crossref
Peter J. Choi, Elizabeth Cooper, Patrick Schweder, Edward Mee, Richard Faull, William A. Denny, Mike Dragunow, Thomas I.-H. Park & Jiney Jose. (2019) The synthesis of a novel Crizotinib heptamethine cyanine dye conjugate that potentiates the cytostatic and cytotoxic effects of Crizotinib in patient-derived glioblastoma cell lines. Bioorganic & Medicinal Chemistry Letters 29:18, pages 2617-2621.
Crossref
Crossref
Saphy Sharda, Ravina Khandelwal, Ritu Adhikary, Diksha Sharma, Manisha Majhi, Tajamul Hussain, Anuraj Nayarisseri & Sanjeev Kumar Singh. (2019) A Computer - Aided Drug Designing for Pharmacological Inhibition of Mutant ALK for the Treatment of Non-small Cell Lung Cancer. Current Topics in Medicinal Chemistry 19:13, pages 1129-1144.
Crossref
Crossref
Peng Zhao, Ling Peng, Wei Wu, Yi Zheng, Weiqin Jiang, Hangyu Zhang, Zhou Tong, Lulu Liu, Ruobing Ma, Liping Wang, Ming Yao, Kai Wang, Weijia Fang & Liming Wu. (2019)
Carcinoma of Unknown Primary with
EML4-ALK
Fusion Response to
ALK
Inhibitors
. The Oncologist 24:4, pages 449-454.
Crossref
Crossref
Marilina García-Aranda & Maximino Redondo. (2019) Targeting Receptor Kinases in Colorectal Cancer. Cancers 11:4, pages 433.
Crossref
Crossref
Tong Wu & Liwu Fu. 2019. Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy. Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy
45
52
.
Eric J. Lowe & Laurence Brugieres. 2019. Non-Hodgkin's Lymphoma in Childhood and Adolescence. Non-Hodgkin's Lymphoma in Childhood and Adolescence
251
262
.
Ying Dai, Quanxiang Wei, Christian Schwager, Janina Hanne, Cheng Zhou, Klaus Herfarth, Stefan Rieken, Kenneth E. Lipson, Jürgen Debus & Amir Abdollahi. (2018) Oncogene addiction and radiation oncology: effect of radiotherapy with photons and carbon ions in ALK-EML4 translocated NSCLC. Radiation Oncology 13:1.
Crossref
Crossref
Silky Bedi, Shah A. Khan, Majed M. AbuKhader, Perwez Alam, Nasir A. Siddiqui & Asif Husain. (2018) A comprehensive review on Brigatinib – A wonder drug for targeted cancer therapy in non-small cell lung cancer. Saudi Pharmaceutical Journal 26:6, pages 755-763.
Crossref
Crossref
Julia Paik & Sohita Dhillon. (2018) Alectinib: A Review in Advanced, ALK-Positive NSCLC. Drugs 78:12, pages 1247-1257.
Crossref
Crossref
Sandra Hudson, Dongliang Wang, Frank Middleton, Barbara H. Nevaldine, Rana Naous & Robert E. Hutchison. (2018) Crizotinib induces apoptosis and gene expression changes in ALK+ anaplastic large cell lymphoma cell lines; brentuximab synergizes and doxorubicin antagonizes. Pediatric Blood & Cancer 65:8, pages e27094.
Crossref
Crossref
Zhen Yu & Ronglei Zhao. (2018) Inhibition of anaplastic lymphoma kinase promotes apoptosis and suppresses proliferation in human hepatocellular carcinoma. Anti-Cancer Drugs 29:6, pages 513-519.
Crossref
Crossref
Stefanie Kube, Christian Vokuhl, Tobias Dantonello, Monika Scheer, Erika Hallmen, Simone Feuchtgruber, Gabriele Escherich, Felix Niggli, Ingrid Kuehnle, Thekla von Kalle, Stefan Bielack, Thomas Klingebiel & Ewa Koscielniak. (2018) Inflammatory myofibroblastic tumors—A retrospective analysis of the Cooperative Weichteilsarkom Studiengruppe. Pediatric Blood & Cancer 65:6.
Crossref
Crossref
Pierre‐Yves Michellys. 2018. Successful Drug Discovery. Successful Drug Discovery
131
152
.
Xiao Liu, Long Peng, Yifan Zhou, Youzhi Zhang & John Z. H. Zhang. (2018) Computational Alanine Scanning with Interaction Entropy for Protein–Ligand Binding Free Energies. Journal of Chemical Theory and Computation 14:3, pages 1772-1780.
Crossref
Crossref
Shoraku Ryu, Mitsuhiro Hayashi, Hiroaki Aikawa, Isamu Okamoto, Yasuhiro Fujiwara & Akinobu Hamada. (2018) Heterogeneous distribution of alectinib in neuroblastoma xenografts revealed by matrix-assisted laser desorption ionization mass spectrometry imaging: a pilot study. British Journal of Pharmacology 175:1, pages 29-37.
Crossref
Crossref
Marilena De Mariano, Sara Stigliani, Stefano Moretti, Federica Parodi, Michela Croce, Cinzia Bernardi, Aldo Pagano, Gian Paolo Tonini, Silvano Ferrini & Luca Longo. (2017) A genome-wide microRNA profiling indicates miR-424-5p and miR-503-5p as regulators of ALK expression in neuroblastoma. Oncotarget 8:34, pages 56518-56532.
Crossref
Crossref
M. Drizou, E. A. Kotteas & N. Syrigos. (2017) Treating patients with ALK-rearranged non-small-cell lung cancer: mechanisms of resistance and strategies to overcome it. Clinical and Translational Oncology 19:6, pages 658-666.
Crossref
Crossref
Vijaykumar R. Holla, Yasir Y. Elamin, Ann Marie Bailey, Amber M. Johnson, Beate C. Litzenburger, Yekaterina B. Khotskaya, Nora S. Sanchez, Jia Zeng, Md Abu Shufean, Kenna R. Shaw, John Mendelsohn, Gordon B. Mills, Funda Meric-Bernstam & George R. Simon. (2017) ALK: a tyrosine kinase target for cancer therapy. Molecular Case Studies 3:1, pages a001115.
Crossref
Crossref
Jianzhong Chen, Jinan Wang & Weiliang Zhu. (2017) Mutation L1196M-induced conformational changes and the drug resistant mechanism of anaplastic lymphoma kinase studied by free energy perturbation and umbrella sampling. Physical Chemistry Chemical Physics 19:44, pages 30239-30248.
Crossref
Crossref
Zhihui Liu & Carol J. Thiele. 2017. Diagnostic and Therapeutic Nuclear Medicine for Neuroendocrine Tumors. Diagnostic and Therapeutic Nuclear Medicine for Neuroendocrine Tumors
83
125
.
Jingjing Wu, John Savooji & Delong Liu. (2016) Second- and third-generation ALK inhibitors for non-small cell lung cancer. Journal of Hematology & Oncology 9:1.
Crossref
Crossref
Evangelia Papadimitriou, Evangelia Pantazaka, Penelope Castana, Thomas Tsalios, Alexandros Polyzos & Dimitris Beis. (2016) Pleiotrophin and its receptor protein tyrosine phosphatase beta/zeta as regulators of angiogenesis and cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1866:2, pages 252-265.
Crossref
Crossref
Kai Chen, Fan Lv, Guofeng Xu, Min Zhang, Yeming Wu & Zhixiang Wu. (2016) Phosphoproteomics reveals ALK promote cell progress via RAS/JNK pathway in neuroblastoma. Oncotarget 7:46, pages 75968-75980.
Crossref
Crossref
Jonathan Khalifa, Arya Amini, Sanjay Popat, Laurie E. Gaspar & Corinne Faivre-Finn. (2016) Brain Metastases from NSCLC: Radiation Therapy in the Era of Targeted Therapies. Journal of Thoracic Oncology 11:10, pages 1627-1643.
Crossref
Crossref
D. Antoni, S. Bockel, E. Deutsch & F. Mornex. (2016) Radiothérapie et thérapies ciblées/immunothérapie. Cancer/Radiothérapie 20:6-7, pages 434-441.
Crossref
Crossref
Hee-Sung Chae, Young-Mi Kim & Young-Won Chin. (2016) Atractylodin Inhibits Interleukin-6 by Blocking NPM-ALK Activation and MAPKs in HMC-1. Molecules 21:9, pages 1169.
Crossref
Crossref
Cara B. Gonzales, Jorge J. De La Chapa, Pothana Saikumar, Prajjal K. Singha, Nicholas F. Dybdal-Hargreaves, Jeffery Chavez, Aaron M. Horning, Jamie Parra & Nameer B. Kirma. (2016) Co-targeting ALK and EGFR parallel signaling in oral squamous cell carcinoma. Oral Oncology 59, pages 12-19.
Crossref
Crossref
Andreas WickiMario MandalàDaniela MassiDaniela TavernaHuifang TangBrian A. HemmingsGongda Xue. (2016) Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling. Physiological Reviews 96:3, pages 805-829.
Crossref
Crossref
Wei-Sheng Huang, Shuangying Liu, Dong Zou, Mathew Thomas, Yihan Wang, Tianjun Zhou, Jan Romero, Anna Kohlmann, Feng Li, Jiwei Qi, Lisi Cai, Timothy A. Dwight, Yongjin Xu, Rongsong Xu, Rory Dodd, Angela Toms, Lois Parillon, Xiaohui Lu, Rana Anjum, Sen Zhang, Frank Wang, Jeffrey Keats, Scott D. Wardwell, Yaoyu Ning, Qihong Xu, Lauren E. Moran, Qurish K. Mohemmad, Hyun Gyung Jang, Tim Clackson, Narayana I. Narasimhan, Victor M. Rivera, Xiaotian Zhu, David Dalgarno & William C. Shakespeare. (2016) Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase. Journal of Medicinal Chemistry 59:10, pages 4948-4964.
Crossref
Crossref
Amit Dipak Amin, Lingxiao Li, Soumya S. Rajan, Vijay Gokhale, Matthew J. Groysman, Praechompoo Pongtornpipat, Edgar O. Tapia, Mengdie Wang & Jonathan H. Schatz. (2016) TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors. Oncotarget 7:17, pages 23715-23729.
Crossref
Crossref
Peilong Zhang, Jiaqiang Dong, Boyu Zhong, Deyi Zhang, Hongbin Yuan, Can Jin, Xiangyuan Xu, Hailong Li, Yong Zhou, Zhi Liang, Minghua Ji, Tao Xu, Guowei Song, Ling Zhang, Gang Chen, Xuejing Meng, Desheng Sun, Joe Shih, Ruihao Zhang, Guojun Hou, Chengcheng Wang, Ying Jin & Qiong Yang. (2016) Design and synthesis of novel 3-sulfonylpyrazol-4-amino pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors. Bioorganic & Medicinal Chemistry Letters 26:8, pages 1910-1918.
Crossref
Crossref
Pierre-Yves Michellys, Bei Chen, Tao Jiang, Yunho Jin, Wenshuo Lu, Thomas H. Marsilje, Wei Pei, Tetsuo Uno, Xuefeng Zhu, Baogen Wu, Truc Ngoc Nguyen, Badry Bursulaya, Christian Lee, Nanxin Li, Sungjoon Kim, Tove Tuntland, Bo Liu, Frank Sun, Auzon Steffy & Tami Hood. (2016) Design and synthesis of novel selective anaplastic lymphoma kinase inhibitors. Bioorganic & Medicinal Chemistry Letters 26:3, pages 1090-1096.
Crossref
Crossref
Ryong Nam Kim, Yoon-La Choi, Mi-Sook Lee, Maruja E. Lira, Mao Mao, Derrick Mann, Joshua Stahl, Abel Licon, So Jung Choi, Michael Van Vrancken, Joungho Han, Iwona Wlodarska & Jhingook Kim. (2016) <i>SEC31A-ALK</i> Fusion Gene in Lung Adenocarcinoma. Cancer Research and Treatment 48:1, pages 398-402.
Crossref
Crossref
JIANHUA LIU, HAOSHENG JIN, HONGXIA TIAN, GUODA LIAN, SHAOJIE CHEN, JIAYU LI, XUCHAO ZHANG & DONG MA. (2016) Anaplastic lymphoma kinase protein expression predicts micrometastases and prognosis for patients with hepatocellular carcinoma. Oncology Letters 11:1, pages 213-223.
Crossref
Crossref
Hong Jae Chon, Hye Ryun Kim, Eunah Shin, Chan Kim, Su Jin Heo, Choong-kun Lee, Jin Kyu Park, Sung Hoon Noh, Hyun Cheol Chung & Sun Young Rha. (2015) The Clinicopathologic Features and Prognostic Impact of ALK Positivity in Patients with Resected Gastric Cancer. Annals of Surgical Oncology 22:12, pages 3938-3945.
Crossref
Crossref
Ulrike Wehkamp, Ilske Oschlies, Inga Nagel, Jochen Brasch, Michael Kneba, Andreas Günther, Wolfram Klapper & Michael Weichenthal. (2015) ALK-positive primary cutaneous T-cell-lymphoma (CTCL) with unusual clinical presentation and aggressive course. Journal of Cutaneous Pathology 42:11, pages 870-877.
Crossref
Crossref
Michela Boi, Emanuele Zucca, Giorgio Inghirami & Francesco Bertoni. (2015) Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas. British Journal of Haematology 168:6, pages 771-783.
Crossref
Crossref
Ying Dai, Quanxiang Wei, Christian Schwager, Mahmoud Moustafa, Cheng Zhou, Kenneth E. Lipson, Wilko Weichert, Jürgen Debus & Amir Abdollahi. (2015) Synergistic effects of crizotinib and radiotherapy in experimental EML4–ALK fusion positive lung cancer. Radiotherapy and Oncology 114:2, pages 173-181.
Crossref
Crossref
Alfred Buhagiar & Duncan Ayers. (2015) Chemoresistance, Cancer Stem Cells, and miRNA Influences: The Case for Neuroblastoma. Analytical Cellular Pathology 2015, pages 1-8.
Crossref
Crossref
Xiaoming Xing & Andrew L. Feldman. (2015) Anaplastic Large Cell Lymphomas. Advances in Anatomic Pathology 22:1, pages 29-49.
Crossref
Crossref
Vassiliki Kotoula, Mattheos Bobos, Maria Vassilakopoulou, Eleftheria Tsolaki, Sofia Chrisafi, Amanda Psyrri, George Lazaridis, Kyriaki Papadopoulou, Ioannis Efstratiou, Catherine Michail-Strantzia, Larisa V. Debelenko, Paris Kosmidis & George Fountzilas. (2015) Intact or Broken-apart RNA. Applied Immunohistochemistry & Molecular Morphology 23:1, pages 60-70.
Crossref
Crossref
L.M. Kopp & E. Katsanis. 2015. Reference Module in Biomedical Sciences. Reference Module in Biomedical Sciences.
Lisa M. Kopp & Emmanuel Katsanis. 2015. Cancer Immunology. Cancer Immunology
47
67
.
Martin Holcmann, Nicole Amberg, Barbara Drobits, Elisabeth Glitzner, Karin Komposch, Jonathan Robson, Fabio Savarese, Sriram Srivatsa, Gabriel Stulnig & Maria Sibilia. 2015. Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease. Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease
279
438
.
Devin C Koestler, Prabhakar Chalise, Mine S Cicek, Julie M Cunningham, Sebastian Armasu, Melissa C Larson, Jeremy Chien, Matthew Block, Kimberly R Kalli, Thomas A Sellers, Brooke L Fridley & Ellen L Goode. (2014) Integrative genomic analysis identifies epigenetic marks that mediate genetic risk for epithelial ovarian cancer. BMC Medical Genomics 7:1.
Crossref
Crossref
Hongbing Zhang, Lily I. Pao, Aileen Zhou, Arthur D. Brace, Robert Halenbeck, Amy W. Hsu, Thomas L. Bray, Kevin Hestir, Elizabeth Bosch, Ernestine Lee, Gang Wang, Haixia Liu, Brian R. Wong, W. Michael Kavanaugh & Lewis T. Williams. (2014) Deorphanization of the human leukocyte tyrosine kinase (LTK) receptor by a signaling screen of the extracellular proteome. Proceedings of the National Academy of Sciences 111:44, pages 15741-15745.
Crossref
Crossref
François Autelitano, Denis Loyaux, Sébastien Roudières, Catherine Déon, Frédérique Guette, Philippe Fabre, Qinggong Ping, Su Wang, Romane Auvergne, Vasudeo Badarinarayana, Michael Smith, Jean-Claude Guillemot, Steven A. Goldman, Sridaran Natesan, Pascual Ferrara & Paul August. (2014) Identification of Novel Tumor-Associated Cell Surface Sialoglycoproteins in Human Glioblastoma Tumors Using Quantitative Proteomics. PLoS ONE 9:10, pages e110316.
Crossref
Crossref
Justin F. Gainor & Alice T. Shaw. 2014. Lung Cancer. Lung Cancer
541
556
.
Qinhua Huang, Ted W. Johnson, Simon Bailey, Alexei Brooun, Kevin D. Bunker, Benjamin J. Burke, Michael R. Collins, Andrew S. Cook, J. Jean Cui, Kevin N. Dack, Judith G. Deal, Ya-Li Deng, Dac Dinh, Lars D. Engstrom, Mingying He, Jacqui Hoffman, Robert L. Hoffman, Patrick S. Johnson, Robert S. Kania, Hieu Lam, Justine L. Lam, Phuong T. Le, Qiuhua Li, Laura Lingardo, Wei Liu, Melissa West Lu, Michele McTigue, Cynthia L. Palmer, Paul F. Richardson, Neal W. Sach, Hong Shen, Tod Smeal, Graham L. Smith, Albert E. Stewart, Sergei Timofeevski, Konstantinos Tsaparikos, Hui Wang, Huichun Zhu, Jinjiang Zhu, Helen Y. Zou & Martin P. Edwards. (2014) Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib. Journal of Medicinal Chemistry 57:4, pages 1170-1187.
Crossref
Crossref
David ParkerMarc-Antoine Belaud-Rotureau. (2014)
Micro-cost Analysis of
ALK
Rearrangement Testing by FISH to Determine Eligibility for Crizotinib Therapy in NSCLC: Implications for Cost Effectiveness of Testing and Treatment
. Clinical Medicine Insights: Oncology 8, pages CMO.S19236.
Crossref
Crossref
Hiroshige Yoshioka, Makoto Nishio, Katsuyuki Kiura, Takashi Seto, Kazuhiko Nakagawa, Makoto Maemondo, Akira Inoue, Toyoaki Hida, Tomohiro Tanaka & Tomohide Tamura. (2014) Phase I/II Study of Alectinib (CH5424802/RO5424802) in Patients with ALK-rearranged Non-small Cell Lung Cancer (NSCLC): Updated Results from the AF-001JP Trial. Haigan 54:7, pages 892-897.
Crossref
Crossref
Tariq Al-Zaid, Neeta Somaiah & Alexander J Lazar. (2014) Targeted therapies for sarcomas: new roles for the pathologist. Histopathology 64:1, pages 119-133.
Crossref
Crossref
Gordana Raca, Jo-Anne van der Krogt, Michelle M. Le Beau & Iwona Wlodarska. 2014. Rare Lymphomas. Rare Lymphomas
17
60
.
Karen Pulford. 2015. Molecular Oncology. Molecular Oncology
162
189
.
D. Ross Camidge, Margaret Skokan, Porntip Kiatsimkul, Barbara Helfrich, Xian Lu, Anna E. Barón, Nathan Schulte, DeLee Maxson, Dara L. Aisner, Wilbur A. Franklin, Robert C. Doebele & Marileila Varella-Garcia. (2013) Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer. Cancer 119:22, pages 3968-3975.
Crossref
Crossref
Adrian Mariño-Enríquez & Paola Dal Cin. (2013) ALK as a paradigm of oncogenic promiscuity: different mechanisms of activation and different fusion partners drive tumors of different lineages. Cancer Genetics 206:11, pages 357-373.
Crossref
Crossref
László Kékesi, Anna Sipos, Gábor Németh, János Pató, Nóra Breza, Ferenc Baska, László Őrfi & György Kéri. (2013) Synthesis and biological evaluation of novel pyrido[2,3-b]pyrazines inhibiting both erlotinib-sensitive and erlotinib-resistant cell lines. Bioorganic & Medicinal Chemistry Letters 23:22, pages 6152-6155.
Crossref
Crossref
Muhammad Latif, Aamer Saeed & Seong Hwan Kim. (2013) Journey of the ALK-inhibitor CH5424802 to phase II clinical trial. Archives of Pharmacal Research 36:9, pages 1051-1054.
Crossref
Crossref
Jianyong Chen, Cheng Jiang & Shaomeng Wang. (2013) LDK378: A Promising Anaplastic Lymphoma Kinase (ALK) Inhibitor. Journal of Medicinal Chemistry 56:14, pages 5673-5674.
Crossref
Crossref
Thomas H. Marsilje, Wei Pei, Bei Chen, Wenshuo Lu, Tetsuo Uno, Yunho Jin, Tao Jiang, Sungjoon Kim, Nanxin Li, Markus Warmuth, Yelena Sarkisova, Frank Sun, Auzon Steffy, AnneMarie C. Pferdekamper, Allen G. Li, Sean B. Joseph, Young Kim, Bo Liu, Tove Tuntland, Xiaoming Cui, Nathanael S. Gray, Ruo Steensma, Yongqin Wan, Jiqing Jiang, Greg Chopiuk, Jie Li, W. Perry Gordon, Wendy Richmond, Kevin Johnson, Jonathan Chang, Todd Groessl, You-Qun He, Andrew Phimister, Alex Aycinena, Christian C. Lee, Badry Bursulaya, Donald S. Karanewsky, H. Martin Seidel, Jennifer L. Harris & Pierre-Yves Michellys. (2013)
Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-
N
2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-
N
4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials
. Journal of Medicinal Chemistry 56:14, pages 5675-5690.
Crossref
Crossref
Vimal Patel & Biren Saraiya. 2013. Handbook of Therapeutic Biomarkers in Cancer. Handbook of Therapeutic Biomarkers in Cancer
449
472
.
Takashi Seto, Katsuyuki Kiura, Makoto Nishio, Kazuhiko Nakagawa, Makoto Maemondo, Akira Inoue, Toyoaki Hida, Nobuyuki Yamamoto, Hiroshige Yoshioka, Masao Harada, Yuichiro Ohe, Naoyuki Nogami, Kengo Takeuchi, Tadashi Shimada, Tomohiro Tanaka & Tomohide Tamura. (2013) CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study. The Lancet Oncology 14:7, pages 590-598.
Crossref
Crossref
Eric J. Lowe & Megan S. Lim. (2013) Potential Therapies for Anaplastic Lymphoma Kinase-Driven Tumors in Children: Progress to Date. Pediatric Drugs 15:3, pages 163-169.
Crossref
Crossref
Andrew J. Weickhardt, Dara L. Aisner, Wilbur A. Franklin, Marileila Varella‐Garcia, Robert C. Doebele & D. Ross Camidge. (2012) Diagnostic assays for identification of anaplastic lymphoma kinase‐positive non–small cell lung cancer. Cancer 119:8, pages 1467-1477.
Crossref
Crossref
Srishma Sridhar, Batool Al-Moallem, Hawra Kamal, Marta Terrile & Raymond L. Stallings. (2013) New Insights into the Genetics of Neuroblastoma. Molecular Diagnosis & Therapy 17:2, pages 63-69.
Crossref
Crossref
Cindy L O'Bryant, Sarah D Wenger, Miryoung Kim & Lisa A Thompson. (2013)
Crizotinib: A New Treatment Option for
ALK
-Positive Non-Small Cell Lung Cancer
. Annals of Pharmacotherapy 47:2, pages 189-197.
Crossref
Crossref
Alex Cazes, Caroline Louis-Brennetot, Pierre Mazot, Florent Dingli, Bérangère Lombard, Valentina Boeva, Romain Daveau, Julie Cappo, Valérie Combaret, Gudrun Schleiermacher, Stéphanie Jouannet, Sandrine Ferrand, Gaëlle Pierron, Emmanuel Barillot, Damarys Loew, Marc Vigny, Olivier Delattre & Isabelle Janoueix-Lerosey. (2013)
Characterization of Rearrangements Involving the
ALK
Gene Reveals a Novel Truncated Form Associated with Tumor Aggressiveness in Neuroblastoma
. Cancer Research 73:1, pages 195-204.
Crossref
Crossref
Fredika M. Robertson & Massimo Cristofanilli. (2012) New Therapeutic Targets in Inflammatory Breast Cancer. Current Breast Cancer Reports 4:4, pages 264-270.
Crossref
Crossref
Judy Quiju Shi, Kerri Lasky, Vaishali Shinde, Bradley Stringer, Mark G. Qian, Debra Liao, Ray Liu, Denise Driscoll, Michelle Tighe Nestor, Benjamin S. Amidon, Youlan Rao, Matt O. Duffey, Mark G. Manfredi, Tricia J. Vos, Natalie D' Amore & Marc L. Hyer. (2012)
MLN0905, a Small-Molecule
PLK1
Inhibitor, Induces Antitumor Responses in Human Models of Diffuse Large B-cell Lymphoma
. Molecular Cancer Therapeutics 11:9, pages 2045-2053.
Crossref
Crossref
Andres Morales La Madrid, Nicholas Campbell, Sonali Smith, Susan L. Cohn & Ravi Salgia. (2012) Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin’s lymphoma, and neuroblastoma. Targeted Oncology 7:3, pages 199-210.
Crossref
Crossref
Charu Thakral, Robert E. Hutchison, Antony Shrimpton, Donna Barrett, Joseph Laver, Michael Link, Devin R. Halleran & Sandra Hudson. (2012) ALK+ anaplastic large cell lymphoma exhibits phosphatidylinositol-3 kinase/akt activity with retained but inactivated PTEN-A report from the Children's Oncology Group. Pediatric Blood & Cancer 59:3, pages 440-447.
Crossref
Crossref
Luca Mologni & Carlo Gambacorti-Passerini. (2012) New developments in the treatment of ALK-driven malignancies. Clinical Investigation 2:8, pages 835-852.
Crossref
Crossref
Luis Cabezón-Gutiérrez, Parham Khosravi-Shahi, Victor Manuel Diaz-Muñoz-de-la-Espada, Jose Rafael Carrión-Galindo, Itziar Eraña-Tomás & María Castro-Otero. (2012) ALK-Mutated Non-Small-Cell Lung Cancer: A New Strategy for Cancer Treatment. Lung 190:4, pages 381-388.
Crossref
Crossref
Hong Ren, Zhi-Ping Tan, Xin Zhu, Katherine Crosby, Herbert Haack, Jian-Min Ren, Sean Beausoleil, Albrecht Moritz, Gregory Innocenti, John Rush, Yi Zhang, Xin-Min Zhou, Ting-Lei Gu, Yi-Feng Yang & Michael J. Comb. (2012) Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer. Cancer Research 72:13, pages 3312-3323.
Crossref
Crossref
Zuzana Tothova & Andrew J. Wagner. (2012) Anaplastic lymphoma kinase-directed therapy in inflammatory myofibroblastic tumors. Current Opinion in Oncology 24:4, pages 409-413.
Crossref
Crossref
Qiang Yan, Hui-Lian Huang, Xing Yao, Jing Li, Li-Qin Li, Jing Zhong, Li-Shan Min, Li-Cheng Dai & Shu-Sen Zheng. (2012) Novel functional proteins interact with midkine in hepatic cancer cells. Hepatobiliary & Pancreatic Diseases International 11:3, pages 272-277.
Crossref
Crossref
Diane E. Gingrich, Joseph G. Lisko, Matthew A. Curry, Mangeng Cheng, Matthew Quail, Lihui Lu, Weihua Wan, Mark S. Albom, Thelma S. Angeles, Lisa D. Aimone, R. Curtis Haltiwanger, Kevin Wells-Knecht, Gregory R. Ott, Arup K. Ghose, Mark A. Ator, Bruce Ruggeri & Bruce D. Dorsey. (2012) Discovery of an Orally Efficacious Inhibitor of Anaplastic Lymphoma Kinase. Journal of Medicinal Chemistry 55:10, pages 4580-4593.
Crossref
Crossref
D. Ross Camidge & Robert C. Doebele. (2012) Treating ALK-positive lung cancer—early successes and future challenges. Nature Reviews Clinical Oncology 9:5, pages 268-277.
Crossref
Crossref
Mangeng Cheng, Matthew R. Quail, Diane E. Gingrich, Gregory R. Ott, Lihui Lu, Weihua Wan, Mark S. Albom, Thelma S. Angeles, Lisa D. Aimone, Flavio Cristofani, Rodolfo Machiorlatti, Cristina Abele, Mark A. Ator, Bruce D. Dorsey, Giorgio Inghirami & Bruce A. Ruggeri. (2012) CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers. Molecular Cancer Therapeutics 11:3, pages 670-679.
Crossref
Crossref
Bettina Bisig, Philippe Gaulard & Laurence de Leval. (2012) New biomarkers in T-cell lymphomas. Best Practice & Research Clinical Haematology 25:1, pages 13-28.
Crossref
Crossref
Floor A.M. Duijkers, José Gaal, Jules P.P. Meijerink, Pieter Admiraal, Rob Pieters, Ronald R. de Krijger & Max M. van Noesel. (2012) High Anaplastic Lymphoma Kinase Immunohistochemical Staining in Neuroblastoma and Ganglioneuroblastoma Is an Independent Predictor of Poor Outcome. The American Journal of Pathology 180:3, pages 1223-1231.
Crossref
Crossref
Marian C. Bryan, Douglas A. Whittington, Elizabeth M. Doherty, James R. Falsey, Alan C. Cheng, Renee Emkey, Rachael L. Brake & Richard T. Lewis. (2012) Rapid Development of Piperidine Carboxamides as Potent and Selective Anaplastic Lymphoma Kinase Inhibitors. Journal of Medicinal Chemistry 55:4, pages 1698-1705.
Crossref
Crossref
J. Devon Roll & Gary W. Reuther. (2012) ALK-Activating Homologous Mutations in LTK Induce Cellular Transformation. PLoS ONE 7:2, pages e31733.
Crossref
Crossref
Kazutomo Kinoshita, Kohsuke Asoh, Noriyuki Furuichi, Toshiya Ito, Hatsuo Kawada, Sousuke Hara, Jun Ohwada, Takuho Miyagi, Takamitsu Kobayashi, Kenji Takanashi, Toshiyuki Tsukaguchi, Hiroshi Sakamoto, Takuo Tsukuda & Nobuhiro Oikawa. (2012) Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802). Bioorganic & Medicinal Chemistry 20:3, pages 1271-1280.
Crossref
Crossref
Eugen F. Mesaros, Tho V. Thieu, Gregory J. Wells, Craig A. Zificsak, Jason C. Wagner, Henry J. Breslin, Rabindranath Tripathy, James L. Diebold, Robert J. McHugh, Ashley T. Wohler, Matthew R. Quail, Weihua Wan, Lihui Lu, Zeqi Huang, Mark S. Albom, Thelma S. Angeles, Kevin J. Wells-Knecht, Lisa D. Aimone, Mangeng Cheng, Mark A. Ator, Gregory R. Ott & Bruce D. Dorsey. (2011)
Strategies to Mitigate the Bioactivation of 2-Anilino-7-Aryl-Pyrrolo[2,1-
f
][1,2,4]triazines: Identification of Orally Bioavailable, Efficacious ALK Inhibitors
. Journal of Medicinal Chemistry 55:1, pages 115-125.
Crossref
Crossref
Keith S. Learn, Jason C. Wagner, Mark S. Albom, Thelma S. Angeles, Zeqi Huang, Arup K. Ghose, Weihua Wan, Mangeng Cheng, Bruce D. Dorsey & Gregory R. Ott. (2012) Design of 7-amino-6-chloro-3H-imidazo[4,5-b]pyridine scaffold from 5-chloro-2,4-diaminopyrimidine pharmacophore: identification of potent inhibitors of anaplastic lymphoma kinase. MedChemComm 3:9, pages 1138.
Crossref
Crossref
Kazutomo Kinoshita, Nobuhiro Oikawa & Takuo Tsukuda. 2012. Annual Reports in Medicinal Chemistry Volume 47. Annual Reports in Medicinal Chemistry Volume 47
281
293
.
Matthew P. Walters & Eduardo V. Zambrano. 2012. Pediatric Neoplasia. Pediatric Neoplasia
169
197
.
Sen Zhang, Frank Wang, Jeffrey Keats, Xiaotian Zhu, Yaoyu Ning, Scott D. Wardwell, Lauren Moran, Qurish K. Mohemmad, Rana Anjum, Yihan Wang, Narayana I. Narasimhan, David Dalgarno, William C. Shakespeare, Juan J. Miret, Tim Clackson & Victor M. Rivera. (2011) Crizotinib‐Resistant Mutants of EML4‐ALK Identified Through an Accelerated Mutagenesis Screen. Chemical Biology & Drug Design 78:6, pages 999-1005.
Crossref
Crossref
Daniela Di Paolo, Chiara Ambrogio, Fabio Pastorino, Chiara Brignole, Cinzia Martinengo, Roberta Carosio, Monica Loi, Gabriella Pagnan, Laura Emionite, Michele Cilli, Domenico Ribatti, Theresa M Allen, Roberto Chiarle, Mirco Ponzoni & Patrizia Perri. (2011) Selective Therapeutic Targeting of the Anaplastic Lymphoma Kinase With Liposomal siRNA Induces Apoptosis and Inhibits Angiogenesis in Neuroblastoma. Molecular Therapy 19:12, pages 2201-2212.
Crossref
Crossref
Rabindranath Tripathy, Robert J. McHugh, Arup K. Ghose, Gregory R. Ott, Thelma S. Angeles, Mark S. Albom, Zeck Huang, Lisa D. Aimone, Mangeng Cheng & Bruce D. Dorsey. (2011) Pyrazolone-based anaplastic lymphoma kinase (ALK) inhibitors: Control of selectivity by a benzyloxy group. Bioorganic & Medicinal Chemistry Letters 21:24, pages 7261-7264.
Crossref
Crossref
Yung-Jue Bang. (2011) The potential for crizotinib in non-small cell lung cancer: a perspective review. Therapeutic Advances in Medical Oncology 3:6, pages 279-291.
Crossref
Crossref
Anna M. Azarova, Gargi Gautam & Rani E. George. (2011) Emerging importance of ALK in neuroblastoma. Seminars in Cancer Biology 21:4, pages 267-275.
Crossref
Crossref
Floor A. M. Duijkers, José Gaal, Jules P. P. Meijerink, Pieter Admiraal, Rob Pieters, Ronald R. de Krijger & Max M. van Noesel. (2011) Anaplastic lymphoma kinase (ALK) inhibitor response in neuroblastoma is highly correlated with ALK mutation status, ALK mRNA and protein levels. Cellular Oncology 34:5, pages 409-417.
Crossref
Crossref
Gregory R. Ott, Gregory J. Wells, Tho V. Thieu, Matthew R. Quail, Joseph G. Lisko, Eugen F. Mesaros, Diane E. Gingrich, Arup K. Ghose, Weihua Wan, Lihui Lu, Mangeng Cheng, Mark S. Albom, Thelma S. Angeles, Zeqi Huang, Lisa D. Aimone, Mark A. Ator, Bruce A. Ruggeri & Bruce D. Dorsey. (2011)
2,7-Disubstituted-pyrrolo[2,1-
f
][1,2,4]triazines: New Variant of an Old Template and Application to the Discovery of Anaplastic Lymphoma Kinase (ALK) Inhibitors with in Vivo Antitumor Activity
. Journal of Medicinal Chemistry 54:18, pages 6328-6341.
Crossref
Crossref
Kazutomo Kinoshita, Takamitsu Kobayashi, Kohsuke Asoh, Noriyuki Furuichi, Toshiya Ito, Hatsuo Kawada, Sousuke Hara, Jun Ohwada, Kazuo Hattori, Takuho Miyagi, Woo-Sang Hong, Min-Jeong Park, Kenji Takanashi, Toshiyuki Tsukaguchi, Hiroshi Sakamoto, Takuo Tsukuda & Nobuhiro Oikawa. (2011)
9-Substituted 6,6-Dimethyl-11-oxo-6,11-dihydro-5
H
-benzo[
b
]carbazoles as Highly Selective and Potent Anaplastic Lymphoma Kinase Inhibitors
. Journal of Medicinal Chemistry 54:18, pages 6286-6294.
Crossref
Crossref
Antonella Barreca, Elena Lasorsa, Ludovica Riera, Rodolfo Machiorlatti, Roberto Piva, Maurilio Ponzoni, Ivo Kwee, Francesco Bertoni, Pier Paolo Piccaluga, Stefano A Pileri, Giorgio Inghirami & _ _. (2011) Anaplastic lymphoma kinase in human cancer. Journal of Molecular Endocrinology 47:1, pages R11-R23.
Crossref
Crossref
Johannes H. Schulte, Hagen S. Bachmann, Bent Brockmeyer, Katleen DePreter, André Oberthür, Sandra Ackermann, Yvonne Kahlert, Kristian Pajtler, Jessica Theissen, Frank Westermann, Jo Vandesompele, Frank Speleman, Frank Berthold, Angelika Eggert, Benedikt Brors, Barbara Hero, Alexander Schramm & Matthias Fischer. (2011)
High
ALK
Receptor Tyrosine Kinase Expression Supersedes
ALK
Mutation as a Determining Factor of an Unfavorable Phenotype in Primary Neuroblastoma
. Clinical Cancer Research 17:15, pages 5082-5092.
Crossref
Crossref
Giorgio Inghirami & Stefano A. Pileri. (2011) Anaplastic large-cell lymphoma. Seminars in Diagnostic Pathology 28:3, pages 190-201.
Crossref
Crossref
P. Jake Slavish, Jeanine E. Price, Qin Jiang, Xiaoli Cui, Stephan W. Morris & Thomas R. Webb. (2011) Synthesis of an aryloxy oxo pyrimidinone library that displays ALK-selective inhibition. Bioorganic & Medicinal Chemistry Letters 21:15, pages 4592-4596.
Crossref
Crossref
Olaf Merkel, Frank Hamacher, Eveline Sifft, Lukas Kenner & Richard Greil. (2011) Novel Therapeutic Options in Anaplastic Large Cell Lymphoma: Molecular Targets and Immunological Tools. Molecular Cancer Therapeutics 10:7, pages 1127-1136.
Crossref
Crossref
Craig A. Zificsak, Jay P. Theroff, Lisa D. Aimone, Thelma S. Angeles, Mark S. Albom, Mangeng Cheng, Eugen F. Mesaros, Gregory R. Ott, Matthew R. Quail, Ted L. Underiner, Weihua Wan & Bruce D. Dorsey. (2011) Methanesulfonamido-cyclohexylamine derivatives of 2,4-diaminopyrimidine as potent ALK inhibitors. Bioorganic & Medicinal Chemistry Letters 21:13, pages 3877-3880.
Crossref
Crossref
Daniela Di Paolo, Chiara Brignole, Fabio Pastorino, Roberta Carosio, Alessia Zorzoli, Marzia Rossi, Monica Loi, Gabriella Pagnan, Laura Emionite, Michele Cilli, Silvia Bruno, Roberto Chiarle, Theresa M Allen, Mirco Ponzoni & Patrizia Perri. (2011) Neuroblastoma-targeted Nanoparticles Entrapping siRNA Specifically Knockdown ALK. Molecular Therapy 19:6, pages 1131-1140.
Crossref
Crossref
Kazutomo Kinoshita, Yoshiyuki Ono, Takashi Emura, Kohsuke Asoh, Noriyuki Furuichi, Toshiya Ito, Hatsuo Kawada, Shota Tanaka, Kenji Morikami, Toshiyuki Tsukaguchi, Hiroshi Sakamoto, Takuo Tsukuda & Nobuhiro Oikawa. (2011) Discovery of novel tetracyclic compounds as anaplastic lymphoma kinase inhibitors. Bioorganic & Medicinal Chemistry Letters 21:12, pages 3788-3793.
Crossref
Crossref
Xianming Deng, Jinhua Wang, Jianming Zhang, Taebo Sim, Nam Doo Kim, Takaaki Sasaki, William LutherIIII, Rani E. George, Pasi A. Jänne & Nathanael S. Gray. (2011) Discovery of 3,5-Diamino-1,2,4-triazole Ureas as Potent Anaplastic Lymphoma Kinase Inhibitors. ACS Medicinal Chemistry Letters 2:5, pages 379-384.
Crossref
Crossref
P Mazot, A Cazes, M C Boutterin, A Figueiredo, V Raynal, V Combaret, B Hallberg, R H Palmer, O Delattre, I Janoueix-Lerosey & M Vigny. (2011) The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking. Oncogene 30:17, pages 2017-2025.
Crossref
Crossref
Enrique Grande, María-Victoria Bolós & Edurne Arriola. (2011) Targeting Oncogenic ALK: A Promising Strategy for Cancer Treatment. Molecular Cancer Therapeutics 10:4, pages 569-579.
Crossref
Crossref
Federica ParodiLorena PassoniLuisa MassimoRoberto LukschClaudio GambiniElena RossiOrsetta ZuffardiVito PistoiaAnnalisa Pezzolo. (2011) Identification of Novel Prognostic Markers in Relapsing Localized Resectable Neuroblastoma. OMICS: A Journal of Integrative Biology 15:3, pages 113-121.
Crossref
Crossref
Larisa V Debelenko, Susana C Raimondi, Najat Daw, Bangalore R Shivakumar, Dali Huang, Marilu Nelson & Julia A Bridge. (2011) Renal cell carcinoma with novel VCL–ALK fusion: new representative of ALK-associated tumor spectrum. Modern Pathology 24:3, pages 430-442.
Crossref
Crossref
Marsha C. Kinney, Russell A. Higgins & Edward A. Medina. (2011) Anaplastic Large Cell Lymphoma: Twenty-Five Years of Discovery. Archives of Pathology & Laboratory Medicine 135:1, pages 19-43.
Crossref
Crossref
Eugen F. Mesaros, Jason P. Burke, Jonathan D. Parrish, Benjamin J. Dugan, Andrew V. Anzalone, Thelma S. Angeles, Mark S. Albom, Lisa D. Aimone, Matthew R. Quail, Weihua Wan, Lihui Lu, Zeqi Huang, Mark A. Ator, Bruce A. Ruggeri, Mangeng Cheng, Gregory R. Ott & Bruce D. Dorsey. (2011) Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse models. Bioorganic & Medicinal Chemistry Letters 21:1, pages 463-466.
Crossref
Crossref
Gregory R. Ott, Rabindranath Tripathy, Mangeng Cheng, Robert McHugh, Andrew V. Anzalone, Ted L. Underiner, Matthew A. Curry, Matthew R. Quail, Lihui Lu, Weihua Wan, Thelma S. Angeles, Mark S. Albom, Lisa D. Aimone, Mark A. Ator, Bruce A. Ruggeri & Bruce D. Dorsey. (2010) Discovery of a Potent Inhibitor of Anaplastic Lymphoma Kinase with in Vivo Antitumor Activity. ACS Medicinal Chemistry Letters 1:9, pages 493-498.
Crossref
Crossref
E. Ardini, P. Magnaghi, P. Orsini, A. Galvani & M. Menichincheri. (2010) Anaplastic Lymphoma Kinase: Role in specific tumours, and development of small molecule inhibitors for cancer therapy. Cancer Letters 299:2, pages 81-94.
Crossref
Crossref
P. Jake Slavish, Jeanine E. Price, Parimala Hanumesh & Thomas R. Webb. (2010) Efficient Synthesis of Pyrazolopyrimidine Libraries. Journal of Combinatorial Chemistry 12:6, pages 807-809.
Crossref
Crossref
Julie Teruya-Feldstein. (2010) The Immunohistochemistry Laboratory: Looking at Molecules and Preparing for Tomorrow. Archives of Pathology & Laboratory Medicine 134:11, pages 1659-1665.
Crossref
Crossref
G. Delsol. (2010) Les anomalies moléculaires dans les lymphomes. Bulletin du Cancer 97:11, pages 1347-1364.
Crossref
Crossref
James E. Butrynski, David R. D'Adamo, Jason L. Hornick, Paola Dal Cin, Cristina R. Antonescu, Suresh C. Jhanwar, Marc Ladanyi, Marzia Capelletti, Scott J. Rodig, Nikhil Ramaiya, Eunice L. Kwak, Jeffrey W. Clark, Keith D. Wilner, James G. Christensen, Pasi A. Jänne, Robert G. Maki, George D. Demetri & Geoffrey I. Shapiro. (2010)
Crizotinib in
ALK
-Rearranged Inflammatory Myofibroblastic Tumor
. New England Journal of Medicine 363:18, pages 1727-1733.
Crossref
Crossref
I. Judson. (2010) Targeted therapies in soft tissue sarcomas. Annals of Oncology 21, pages vii277-vii280.
Crossref
Crossref
Fergal C. Kelleher & Ray McDermott. (2010) The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene. European Journal of Cancer 46:13, pages 2357-2368.
Crossref
Crossref
I Janoueix-Lerosey, G Schleiermacher & O Delattre. (2010) Molecular pathogenesis of peripheral neuroblastic tumors. Oncogene 29:11, pages 1566-1579.
Crossref
Crossref
Benjamin Solomon, Marileila Varella-Garcia & D Ross Camidge. (2009) ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer. Journal of Thoracic Oncology 4:12, pages 1450-1454.
Crossref
Crossref
Qian Zhang, Hong Y. Wang, Gauri Bhutani, Xiaobin Liu, Michele Paessler, John W. Tobias, Donald Baldwin, Kunchithapadam Swaminathan, Michael C. Milone & Mariusz A. Wasik. (2009) Lack of TNFα expression protects anaplastic lymphoma kinase-positive T-cell lymphoma (ALK+ TCL) cells from apoptosis. Proceedings of the National Academy of Sciences 106:37, pages 15843-15848.
Crossref
Crossref